FDA Plays

[Guy]

TBUFF (0.39) – Tribute Pharmaceuticals is an emerging Canadian specialty pharmaceutical company with a primary focus
on the acquisition, licensing, development and promotion of healthcare products in Canada.
Market Cap: $20M OS Shares: 51.0M

TBUFF has an experienced management team and board, which includes John Gregory who Founded and built King Pharmaceuticals (formerly NYSE:KG) which was sold to Pfizer for $3.6 billion. He is managing partner of SJ Strategic Investments, a family owned investment management firm. Mr. Gregory owns 16% of Tribute.
Robert Harris the President & CEO held executive positions at Biovail Corporation including VP of Business Development and GM of Biovail’s Canadian commercial group ,where he helped grow revenues to $150M within four years, leading to Biovail’s acquisition by Valeant (NYSE:VRX) for $3.2 billion. 20 years at Wyeth, now division of Pfizer (NYSE:PFE),where as Director of Sales of Specialty Care group he built out Canadian market segment.

Insider Ownership: 57%
Insiders bought in 2013 @.40 - .56:
http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions

Tribute Pharmaceuticals Canada Inc.’s current portfolio of assets includes nine products: NeoVisc®, NeoVisc® Single Dose, Uracyst®, BladderChek®, Bezalip® SR, Soriatane®, Cambia®, Daraprim®, Collatamp G® and MycoVa™. Each of these products has received regulatory approval in Canada, with the exception of MycoVa.

TBUFF sells Cambia for acute migraine, in Canada. The medication is sold in a sachet form, a powder mixed with a couple of ounces of water. It is extremely fast acting. Nautilus Neurosciences has licensed Cambia to TBUFF.
A month ago, Depomed acquired Cambia US rights from Nautilus for $49 million:
http://finance.yahoo.com/news/depomed-acquires-cambia-diclofenac-potassium-210500674.html

http://finance.yahoo.com/news/cambia-r-tribute-pharmaceuticals-130000063.html

Another Tribute product is called Bezalip SR which is a fibrate drug intended to lower cholesterol. TBUFF acquired the license to sell the drug in Canada. The company also owns the license to sell Bezalip in the U.S.and filed an IND with the FDA in November:
http://finance.yahoo.com/news/tribute-pharmas-investigational-drug-application-130000337.html

Presentation:
http://content.stockpr.com/tributepharma/media/0a26f60f9fe2b220d091c62d6123d81e.pdf

This might be interesting here being so close to breaking above the 50 and 200 day MA @.39 & .42 respectively.